Protective responses of an engineered PspA recombinant antigen against Streptococcus pneumoniae

Akbari, Elaheh; Negahdari, Babak; Faraji, Fatemeh; Behdani, Mahdi; Kazemi‐Lomedasht, Fatemeh; Habibi‐Anbouhi, Mahdi

doi:10.1016/j.btre.2019.e00385

Cited by 13 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, when the immune human serum was administered to mice infected with pneumococcal pathogens expressing either PspA family 1 or 2, an immune response was elicited, but not as strong against family 2 as against family 1. This reinforces the need for using IL-12 or FlaB-adjuvanted recombinant pneumococcal vaccines (74).…”

Section: Immunization With Pspasupporting

confidence: 64%

Pneumococcal Surface Protein A: A Promising Candidate for the Next Generation of Pneumococcal Vaccines

Alghamdi

Sahibzada

Shesha

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Streptococcus pneumoniae is the bacterium that causes pneumococcal disease which often results in pneumonia, meningitis, otitis media, septicemia and sinusitis. Pneumonia, particularly, is a significant cause of worldwide morbidity and a global health burden as well. Treatment often relies on antimicrobials, to which the pathogen is frequently mutating and rendering infective. Consequently, vaccination is the most effective approach in dealing with pneumococcal antimicrobial resistance (AMR). Unfortunately, the current pneumococcal polysaccharide and conjugate vaccines have a narrow serotype coverage. Therefore, the current need for vaccines with a broader serotype coverage cannot be overstated. Pneumococcal Surface Protein A and C are potential vaccine candidate antigens present in over 90% of the strains from clinical isolates as well as laboratory non-encapsulated strains. Pneumococcal Surface Protein A is an active virulent factor that pneumococci use to evade complement-mediated host immune responses and has been shown to elicit immune responses against pneumococcal infections. This review explores the potential utilization of Pneumococcal Surface Protein A to immunize against S. pneumoniae.

show abstract

Section: Immunization With Pspasupporting

confidence: 64%

Pneumococcal Surface Protein A: A Promising Candidate for the Next Generation of Pneumococcal Vaccines

Alghamdi

Sahibzada

Shesha

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

show abstract

“…However, zmpB has also been shown to be present in closely related commensal streptococcal species colonizing the human host, thereby possibly limiting its vaccine potential ( 39 ). PspA is also present in most pneumococcal strains, albeit exhibiting different alleles ( 40 ), and this protein has also been demonstrated to be protective against pneumococcal disease ( 41 ). Given that these are core proteins, surface-exposed, protective, and now found to be broadly highly expressed by the pneumococcus in vivo, this makes them potentially powerful candidates for the development of a serotype-independent pneumococcal vaccine.…”

Section: Discussionmentioning

confidence: 99%

An in vivo atlas of host–pathogen transcriptomes during Streptococcus pneumoniae colonization and disease

D’Mello

Riegler

Martínez

et al. 2020

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Streptococcus pneumoniae (Spn) colonizes the nasopharynx and can cause pneumonia. From the lungs it spreads to the bloodstream and causes organ damage. We characterized the in vivo Spn and mouse transcriptomes within the nasopharynx, lungs, blood, heart, and kidneys using three Spn strains. We identified Spn genes highly expressed at all anatomical sites and in an organ-specific manner; highly expressed genes were shown to have vital roles with knockout mutants. The in vivo bacterial transcriptome during colonization/disease was distinct from previously reported in vitro transcriptomes. Distinct Spn and host gene-expression profiles were observed during colonization and disease states, revealing specific genes/operons whereby Spn adapts to and influences host sites in vivo. We identified and experimentally verified host-defense pathways induced by Spn during invasive disease, including proinflammatory responses and the interferon response. These results shed light on the pathogenesis of Spn and identify therapeutic targets.

show abstract

“…In addition, the PspAB 1-5 vaccine was able to confer protection in immunized mice against a S. pneumoniae strain from clade 2 in a challenge study. Therefore, the PspA-based vaccine derived from the B region of all clades would be able to confer significant protection against multiple serotypes of S. pneumoniae and could serve as key antigenic epitopes to overcome the limitations of the polysaccharide and conjugated vaccines [73].…”

Section: Protein-based Vaccinesmentioning

confidence: 99%

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

et al. 2020

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S. pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover a wide range of serotypes. This review discusses the new approaches to develop effective vaccines with broad serotype coverage as well as recent development of promising pneumococcal vaccines in clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (Δpep27ΔcomD mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA). Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15 (V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed.

show abstract

Protective responses of an engineered PspA recombinant antigen against Streptococcus pneumoniae

Cited by 13 publications

References 39 publications

Pneumococcal Surface Protein A: A Promising Candidate for the Next Generation of Pneumococcal Vaccines

Pneumococcal Surface Protein A: A Promising Candidate for the Next Generation of Pneumococcal Vaccines

An in vivo atlas of host–pathogen transcriptomes during Streptococcus pneumoniae colonization and disease

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

Contact Info

Product

Resources

About